This noises very futuristic but is not as far-fetched as it might seem. Already people have portable technology for gene sequencing. There are wireless technology that would be in a position to send out the barcode data to a central database for matching and have the result. What is still required is usually miniaturisation of the whole platform – the entire sample preparation. But numerous groups are working upon this. A hand-held program would allow people to carry out quick identification of specimens in the field – in a rain forest, for example, or, closer to home, in a hospital where microbiologists need to identify pathogenic organisms..
Abbott releases details on stage 3 hepatitis C registrational program Abbott today released details on its phase 3 hepatitis C registrational plan following promising outcomes from its phase 2b clinical trial, referred to as Aviator, presented at the Annual Meeting of the American Association for the analysis of Liver Disease in Boston. Yet another phase 3 trial shall study triple-DAAs, with ribavirin, in individuals with cirrhosis for 12 or 24 weeks. An interview with Dr Chhatwal The phase 3 system, which is open for enrollment currently, will include a lot more than 2,000 individuals with HCV genotype 1, with trial sites in 29 countries. The DAAs in the research include ABT-450/r , ABT-267 and ABT-333 . Treatment duration will be 12 weeks in non-cirrhotic individuals, and 12 or 24 weeks in cirrhotic patients.